This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Markers			
Markers for response to peroxisome proliferation-activated receptor- γ (PPARG; PPAR γ) agonist therapy in insulin-resistant patients	<p>A gene expression study in human subjects identified markers that could help predict response to PPARγ agonist therapy in insulin-resistant patients. Following administration of a PPARγ agonist to diabetes patients, expression of <i>MLX interacting protein (MLXIP)</i> in muscle increased, whereas expression of <i>major histocompatibility complex class II DR β1 (HLA-DRB1)</i> in adipose tissue decreased. Next steps include monitoring those two markers and other potential markers in further clinical studies of diabetes patients.</p> <p>Avandia rosiglitazone, an oral PPARγ agonist from GlaxoSmithKline plc, is marketed to treat diabetes.</p> <p>Actos pioglitazone, a PPARγ agonist from Takeda Pharmaceutical Co. Ltd. and Eli Lilly and Co., is also marketed to treat diabetes.</p> <p>SciBX 2(41); doi:10.1038/scibx.2009.1553 Published online Oct. 22, 2009</p>	Work unpatented; licensing status not applicable	<p>Sears, D.D. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Oct. 12, 2009; doi:10.1073/pnas.0903032106 Contact: Shankar Subramaniam, University of California, San Diego, La Jolla, Calif. e-mail: shankar@ucsd.edu Contact: Dorothy D. Sears, same affiliation as above e-mail: dsears@ucsd.edu</p>